Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FL115 + Bacillus Calmette-Guérin
- Development stage
- Unknown
- Lead developer
- Forlong Biotechnology
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
FL115 + Bacillus Calmette-Guérin (BCG) is a combination immunotherapy being developed by Suzhou Forlong Biotechnology for the treatment of non-muscle invasive bladder cancer (NMIBC), including patients who are BCG-unresponsive. FL115 is an engineered interleukin-15 (IL-15)/IL-15 receptor subunit alpha (IL15RA) fusion protein created using F-body technology. It functions as an IL-15 superagonist, designed to enhance anti-tumor immunity by stimulating natural killer (NK) cells and CD8+ T cells while maintaining a small molecular weight for superior tumor penetration and an extended half-life compared to native IL-15. BCG is a live attenuated strain of *Mycobacterium bovis* that induces a potent local immune response in the bladder. The combination therapy is administered intravesically to synergistically activate the immune system against bladder cancer cells.
- Other names
- FL115 + BCG
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on FL115 + Bacillus Calmette-Guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FL115 + Bacillus Calmette-Guérin.